Impact of Polyvalent Mechanical Bacterial Lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial

Małgorzata Bartkowiak-Emeryk, Andrzej Emeryk, Jacek Roliński, Ewelina Wawryk-Gawda, Ewa Markut-Miotła, Małgorzata Bartkowiak-Emeryk, Andrzej Emeryk, Jacek Roliński, Ewelina Wawryk-Gawda, Ewa Markut-Miotła

Abstract

Background: Polyvalent Mechanical Bacterial Lysate (PMBL®) contains antigens of bacteria responsible for respiratory infections. PMBL® has been proven to reduce the number of respiratory infections, and in its use, immunological benefits have been seen in allergic patients. PMBL® activates both innate and specific immune responses. The lysate induces dendritic cells, T and B lymphocytes and IgA secretion, as well as the production of antibodies directed against administered bacterial antigens. Moreover, it increases the response against other bacteria and viruses. The immunologic mechanism of lysate's action is not yet clearly determined. The objective of this study was to assess the effect of PMBL® on T cells in children with allergic asthma.

Methods: This study was a part of the EOLIA study. Herein, 49 children with allergic asthma and house dust mites allergy were included: 21 in PMBL® and 28 in the Placebo group, both, drug and placebo were administered sublingually. The tests were done at baseline and 12 weeks after the last tablet intake. The lymphocytes CD45+, lymphocytes T CD3+, CD3+CD25+, CD3+CD69+, Th CD3+CD4+, CD4+CD25+, CD4+CD25+ high, CD4+CD69+, Treg CD4+CD25+FOXP3, Tc CD3+CD8+, CD8+CD25+, CD8+CD69+, NK-like T CD3+CD16+CD56+ and NK cells CD3-CD16+CD56+ were described.

Results: At baseline, no significant differences between groups relative to blood count cells were observed, except for eosinophils. After 12 weeks, we observed an increase of T lymphocytes count. In addition, CD4+CD25+FOXP3+, CD8+ and CD3-CD16+CD56+ and (insignificantly) Th count increased. However, CD69+ and CD25+ subset of CD3+ significantly decreased.

Conclusions: The EOLIA study demonstrated that PMBL® administration 10 days per month for 3 months changed the panel of T lymphocytes. Trial registration Clinical Trial Registration: This study was a part of the EOLIA (Efficacy Of mechanical bacterial Lysate In Allergic children), a clinical study NCT02541331. Frederic Durmont, MD Lallemand Pharma International AG. Date of registration 09/08/2013. URL of trial registry record: https://ichgcp.net/clinical-trials-registry/NCT02541331.

Keywords: Allergic asthma; Bacterial lysates; Children; Immune; Infection; Lymphocyte; Patients.

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest or financial competing interests with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Morandi B, Agazzi A, D’Agostino A, et al. A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunol Lett. 2011;138(1):86–91. doi: 10.1016/j.imlet.2011.03.006.
    1. Jurkiewicz D, Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol. 2018;72(5):1–8. doi: 10.5604/01.3001.0012.7216.
    1. Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. doi: 10.1016/j.intimp.2017.10.032.
    1. Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJL. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006;4:CD004974. doi: 10.1002/14651858.CD004974.pub2.
    1. Lanzilli G, Traggiai E, Braido F, et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. Immunol Lett. 2013;149(1–2):62–67. doi: 10.1016/j.imlet.2012.11.009.
    1. Braido F, Schenone G, Pallestrini E, et al. The relationship between mucosal immuno-response and clinical outcome in patients with recurrent upper respiratory tract infections treated with a mechanical bacterial lysate. J Biol Regul Homeost Agents. 2011;25(3):477–485.
    1. Lanzilli G, Falchetti R, Cottarelli A, Macchi A, Ungheri D, Fuggetta MP. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol. 2006;19(3):551–559. doi: 10.1177/039463200601900311.
    1. Ricci R, Palmero C, Bazurro G, et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulm Pharmacol Ther. 2014;27(1):109–113. doi: 10.1016/j.pupt.2013.05.006.
    1. Janeczek KP, Emeryk A, Rapiejko P. Effect of polyvalent bacterial lysate on the clinical course of pollen allergic rhinitis in children. Postepy Dermatol Alergol. 2019;36(4):504–505. doi: 10.5114/ada.2019.87457.
    1. Janeczek KP, Emeryk A, Rapiejko P. Effect of polyvalent bacterial lysate on the clinical course of pollen allergic rhinitis in children. Adv Dermatol Allergol Dermatol Alergol. 2019;36(4):504. doi: 10.5114/ada.2019.87457.
    1. Razi CH, Harmancı K, Abacı A, et al. The immuno-stimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010;126(4):763–769. doi: 10.1016/j.jaci.2010.07.038.
    1. Emeryk A, Bartkowiak-Emeryk M, Raus Z, Braido F, Ferlazzo G, Melioli G. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study. Pediatr Allergy Immunol. 2018;29(4):394–401. doi: 10.1111/pai.12894.
    1. Lau S, Gerhold K, Zimmermann K, et al. Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(4):1040–1047. doi: 10.1016/j.jaci.2012.02.005.
    1. Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918–927. doi: 10.1016/j.jaip.2017.05.001.
    1. Busse WW, Lemanske RF, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet Lond Engl. 2010;376(9743):826–834. doi: 10.1016/S0140-6736(10)61380-3.
    1. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128(6):1165–1174. doi: 10.1016/j.jaci.2011.10.024.
    1. Olenec JP, Kim WK, Lee W-M, et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J Allergy Clin Immunol. 2010;125(5):1001–1006.e1. doi: 10.1016/j.jaci.2010.01.059.
    1. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen K-L, Schaad UB. Nonspecific immuno-modulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;18(3):198–209. doi: 10.1097/ACI.0000000000000433.
    1. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549–556. doi: 10.1016/j.jaci.2006.01.011.
    1. 2012-GINA.pdf. . Accessed 1 July 2019.
    1. Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;67:35–45. doi: 10.1016/j.intimp.2018.11.043.
    1. Abdulamir AS, Hafidh RR, Abubakar F, Abbas KA. Changing survival, memory cell compartment, and T-helper balance of lymphocytes between severe and mild asthma. BMC Immunol. 2008;9:73. doi: 10.1186/1471-2172-9-73.
    1. Waserman S, Nair P, Snider D, et al. Local and systemic immunological parameters associated with remission of asthma symptoms in children. Allergy Asthma Clin Immunol. 2012;8(1):16. doi: 10.1186/1710-1492-8-16].
    1. Branchett WJ, Lloyd CM. Regulatory cytokine function in the respiratory tract. Mucosal Immunol. 2019;12(3):589–600. doi: 10.1038/s41385-019-0158-0].
    1. Bajnok A, Ivanova M, Rigó J, Jr, Toldi G. The distribution of activation markers and selectins on peripheral T lymphocytes in preeclampsia. Mediators Inflamm. 2017 doi: 10.1155/2017/8045161.
    1. Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946–953. doi: 10.1002/eji.201646837.
    1. Ryanna K, Stratigou V, Safinia N, Hawrylowicz C. Regulatory T cells in bronchial asthma. Allergy. 2009;64(3):335–347. doi: 10.1111/j.1398-9995.2009.01972.x.
    1. de Boer GM, Braunstahl G-J, Hendriks RW, Tramper GA. Bacterial lysates in the prevention of asthma exacerbations in uncontrolled asthma: the Breathe study. Eur Respir J. 2018;52(suppl 62):5008. doi: 10.1183/13993003.congress-2018.PA5008.
    1. Han R-F, Li H-Y, Wang J-W, Cong X-J. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom. Eur Rev Med Pharmacol Sci. 2016;20(10):2151–2155.
    1. Salter BM, Aw M, Sehmi R. The role of type 2 innate lymphoid cells in eosinophilic asthma. J Leukoc Biol. 2019;106(4):889–901. doi: 10.1002/JLB.3MR1217-497R.
    1. Navarro S, Cossalter G, Chiavaroli C, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011;4(1):53–65. doi: 10.1038/mi.2010.51.
    1. Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T, ed. Immunologia. PWN; 2017.
    1. Nguyen-Thi-Dieu T, Le-Thi-Thu H, Duong-Quy S. The profile of leucocytes, CD3+, CD4+, and CD8+ T cells, and cytokine concentrations in peripheral blood of children with acute asthma exacerbation. J Int Med Res. 2017;45(6):1658–1669. doi: 10.1177/0300060516680439.
    1. Walwyn-Brown K, Guldevall K, Saeed M, et al. Human NK cells Lyse Th2-polarizing dendritic cells via NKp30 and DNAM-1. J Immunol. 2018;201(7):2028–2041. doi: 10.4049/jimmunol.1800475.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다